| Recruiting | A Study of CDX-622 in Participants With Mild to Moderate Asthma Mild to Moderate Asthma | Phase 1 | 2026-02-01 |
| Recruiting | A Study to Investigate Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold I Chronic Inducible Urticaria, Cold Urticaria, Cold-Induced Urticaria | Phase 3 | 2026-01-15 |
| Recruiting | Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Chronic Spontaneous Urticaria | Phase 3 | 2025-11-25 |
| Active Not Recruiting | A Study of Barzolvolimab in Patients With Atopic Dermatitis Atopic Dermatitis | Phase 2 | 2024-12-18 |
| Active Not Recruiting | A Phase I Study of CDX-622 Healthy Participants | Phase 1 | 2024-11-01 |
| Active Not Recruiting | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU) Chronic Spontaneous Urticaria | Phase 3 | 2024-07-19 |
| Active Not Recruiting | A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Chronic Spontaneous Urticaria | Phase 3 | 2024-07-11 |
| Active Not Recruiting | A Study of Barzolvolimab in Patients With Prurigo Nodularis Prurigo Nodularis | Phase 2 | 2024-04-12 |
| Completed | A Study of CDX-0159 in Patients With Eosinophilic Esophagitis Eosinophilic Esophagitis | Phase 2 | 2023-06-01 |
| Completed | A Study of CDX-585 in Patients With Advanced Malignancies Non-small Cell Lung Cancer, Gastric Cancer, Head and Neck Cancer | Phase 1 | 2023-05-11 |
| Completed | A Study of CDX-0159 in Patients With Chronic Inducible Urticaria Chronic Inducible Urticaria | Phase 2 | 2022-06-28 |
| Completed | A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Chronic Spontaneous Urticaria | Phase 2 | 2022-05-19 |
| Completed | A Study of CDX-0159 in Patients With Prurigo Nodularis Prurigo Nodularis | Phase 1 | 2021-11-08 |
| Completed | A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects Healthy Subjects | Phase 1 | 2021-08-30 |
| Completed | A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Con Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism | Phase 1 | 2020-11-24 |
| Completed | A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria Chronic Spontaneous Urticaria | Phase 1 | 2020-09-24 |
| Completed | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer | Phase 1 | 2020-08-04 |
| Completed | A Phase 1 Study of CDX-0159 Healthy Subjects | Phase 1 | 2019-10-29 |
| Terminated | A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | 2018-03-27 |
| Completed | A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies Melanoma, Non-small Cell Lung Cancer, Breast Cancer | Phase 1 | 2017-12-01 |
| Terminated | A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clea Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 1 | 2016-06-01 |
| Completed | A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors Advanced Cancer | Phase 1 | 2015-12-01 |
| Terminated | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms | Phase 1 | 2015-10-01 |
| Completed | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients Squamous Cell Carcinoma of the Head and Neck | Phase 1 | 2015-10-01 |
| Completed | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and K Thyroid Cancer | Phase 1 | 2015-06-01 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms | Phase 1 | 2015-05-01 |
| Terminated | A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Me Unresectable Stage III or Stage IV Melanoma | Phase 1 / Phase 2 | 2015-04-01 |
| Completed | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced R Squamous Cell Carcinoma of the Head and Neck (SCCHN), Ovarian Carcinoma-Enrollment Completed, Colorectal Cancer (CRC)-Enrollment Completed | Phase 1 / Phase 2 | 2015-01-01 |
| Terminated | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanc Melanoma | Phase 2 | 2014-11-01 |
| Terminated | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Re For Donors, Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling, For Recipients | Phase 2 | 2014-07-01 |
| Completed | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Advanced Cancer | Phase 1 | 2014-01-01 |
| Completed | Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative B Metastatic gpNMB Over-expressing Triple Negative Breast Cancer | Phase 2 | 2013-11-01 |
| Terminated | Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease Dense Deposit Disease, Membranoproliferative Glomerulonephritis Type II, C3 Glomerulonephritis | Phase 1 | 2013-01-01 |
| Completed | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma | Phase 2 | 2011-12-01 |
| Completed | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma | Phase 3 | 2011-11-01 |
| Completed | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | 2011-10-01 |
| Completed | A Study to Evaluate CDX-301 (rhuFlt3L) in Healthy Volunteers Healthy | Phase 1 | 2011-10-01 |
| Completed | A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer Breast Cancer | Phase 2 | 2010-07-01 |
| Terminated | A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The " Bladder Cancer | Phase 2 | 2010-04-01 |
| Completed | A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 Advanced Malignancies | Phase 1 / Phase 2 | 2009-09-01 |
| Completed | Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme Malignant Glioma | Phase 2 | 2007-08-01 |
| Completed | Phase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Breast Cancer, Colorectal Cancer, Pancreatic Cancer | Phase 1 | 2006-01-01 |
| Completed | A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX Breast Cancer, Colorectal Cancer, Pancreatic Cancer | Phase 1 | 2004-03-01 |
| No Longer Available | Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut Recurrent GBM | — | — |
| No Longer Available | Individual Patient Expanded Access-Glembatumumab Vedotin Metastatic gpNMB Expressing Triple Negative Breast Cancer | — | — |